KR930007943A - 벤조티아제핀 유도체 - Google Patents

벤조티아제핀 유도체 Download PDF

Info

Publication number
KR930007943A
KR930007943A KR1019920019273A KR920019273A KR930007943A KR 930007943 A KR930007943 A KR 930007943A KR 1019920019273 A KR1019920019273 A KR 1019920019273A KR 920019273 A KR920019273 A KR 920019273A KR 930007943 A KR930007943 A KR 930007943A
Authority
KR
South Korea
Prior art keywords
optionally substituted
compound
composition
cycloalkyl
alkyl
Prior art date
Application number
KR1019920019273A
Other languages
English (en)
Other versions
KR100214902B1 (ko
Inventor
테루오 야시모리
히로시 히라다
가쯔노리 사까이
가즈미 이와끼
가즈끼 마쯔나가
Original Assignee
요시또시 가즈오
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시또시 가즈오, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 요시또시 가즈오
Publication of KR930007943A publication Critical patent/KR930007943A/ko
Application granted granted Critical
Publication of KR100214902B1 publication Critical patent/KR100214902B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ) 및 약학적으로 허용가능한 그의 염에 관한 것이다 :
상기식에서, X는 = N-A-R1또는 = C(R1)R2이고 ; A는 단일결합, 폴리메틸렌 또는 -CO-이고; R1및 R2는 각각 소수, C1-C6알킬, C3-C7사이클로알킬, 치환되지 않거나 치환된 페닐, 임의로 치환된 벤즈 히드릴, 또는 임의로 치환된 5내지 6원 헤테로사이클릭 그룹이고 ; Y는 수소, 할로겐, C1-C6알킬, C3-C7사이클로알킬, C1-C6알콕시, 임의로 치환된 페녹시, 임의로 치환된 벤질옥시, 또는 임의로 치환된 벤질이고 ; Z는 수소 또는 아실이고 ; n은 2내지 6의 정수이다.

Description

벤조티아제핀 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식(Ⅰ)의 화합물 및 약학적으로 허용가능한 그의 염 :
    상기식에서, X는 = N-A-R1또는 = C(R1)R2이고 ; A는 단일결합, 폴리메틸렌 또는 -CO-이고; R1및 R2는 각각 소수, C1-C6알킬, C3-C7사이클로알킬, 치환되지 않거나 치환된 페닐, 임의로 치환된 벤즈 히드릴, 또는 임의로 치환된 5내지 6원 헤테로사이클릭 그룹이고 ; Y는 수소, 할로겐, C1-C6알킬, C3-C7사이클로알킬, C1-C6알콕시, 임의로 치환된 페녹시, 임의로 치환된 벤질옥시, 또는 임의로 치환된 벤질이고 ; Z는 수소 또는 아실이고 ; n은 2내지 6의 정수이다.
  2. 제1항에 있어서, n이 3인 화합물.
  3. 제1항에 있어서, R1이 치환되지 않거나 치환된 페닐인 화합물.
  4. 제1항에 있어서, (2S-시스)-3-아세톡시-5-[3-(2-메톡시페닐)-1-피페라지닐)프로필]-2, 3-디하이드로-2-(4-메톡시페닐)-8-클로로-1, 5-벤조티아제핀-4(5H)-온인 화합물.
  5. 필수 성분으로 제1항의 화합물을 포함한 약학 조성물.
  6. 제5항에 있어서, 고혈압 치료제로 유용한 조성물.
  7. 제5항에 있어서, 심장 질환의 치료에 유용한 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920019273A 1991-10-21 1992-10-20 벤조티아제핀 유도체 KR100214902B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP91-302348 1991-10-21
JP30234891 1991-10-21

Publications (2)

Publication Number Publication Date
KR930007943A true KR930007943A (ko) 1993-05-20
KR100214902B1 KR100214902B1 (ko) 1999-08-02

Family

ID=17907840

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920019273A KR100214902B1 (ko) 1991-10-21 1992-10-20 벤조티아제핀 유도체

Country Status (12)

Country Link
US (2) US5378698A (ko)
EP (2) EP0541263B1 (ko)
JP (1) JP2818082B2 (ko)
KR (1) KR100214902B1 (ko)
CN (1) CN1034075C (ko)
AT (2) ATE116974T1 (ko)
CA (1) CA2080671A1 (ko)
DE (2) DE69201184T2 (ko)
DK (2) DK0615971T3 (ko)
ES (2) ES2069967T3 (ko)
GR (1) GR3024453T3 (ko)
TW (1) TW221429B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709280B2 (en) * 1996-02-23 1999-08-26 Tanabe Seiyaku Co., Ltd. Process for preparing 1,5-benzothiazepine derivative
TW438787B (en) * 1997-02-27 2001-06-07 Tanabe Seiyaku Co Process for preparing optically active trans-3-substituted glycidic acid ester
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
CN1872846B (zh) * 1999-07-09 2010-06-16 宇部兴产株式会社 二苯并硫氮*衍生物的制备方法
AU2001267844A1 (en) * 2000-06-28 2002-01-08 Takeda Chemical Industries Ltd. Method of preparing heart muscle cells and method of searching for remedy for heart diseases
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
MXPA04006281A (es) 2001-12-28 2004-09-27 Acadia Pharm Inc Analogos de tetrahidroquinolina como agonistas muscarinicos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075967A (en) * 1961-06-12 1963-01-29 Olin Mathieson Benzothiazines
US4567175A (en) * 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
US4594342A (en) * 1984-04-10 1986-06-10 Tanabe Seiyaku Co., Ltd. 1,5-benzothiazepine derivative
US4584131A (en) * 1985-06-20 1986-04-22 E. R. Squibb & Sons, Inc. Benzothiazepine derivatives
US5028610A (en) * 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4879289A (en) * 1988-05-24 1989-11-07 Marion Laboratories, Inc. Method of ameliorating epileptic seizures
US4963545A (en) * 1988-05-24 1990-10-16 Marion Laboratories, Inc. Benzothiazepine anti-seizure method
FR2645744B1 (fr) * 1989-04-13 1994-01-21 Roussel Uclaf Derives de la benzothiazepine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions les renfermant
CA2030159A1 (en) * 1989-11-22 1991-05-23 Nahed K. Ahmed Anti-cancer drug potentiators
US5001236A (en) * 1989-11-22 1991-03-19 Marion Laboratories, Inc. Benzothiazepines

Also Published As

Publication number Publication date
JP2818082B2 (ja) 1998-10-30
DK0615971T3 (da) 1997-10-06
US5378698A (en) 1995-01-03
US5462936A (en) 1995-10-31
ES2069967T3 (es) 1995-05-16
ES2106439T3 (es) 1997-11-01
CN1034075C (zh) 1997-02-19
EP0541263B1 (en) 1995-01-11
EP0615971A1 (en) 1994-09-21
DE69201184D1 (de) 1995-02-23
EP0541263A1 (en) 1993-05-12
CA2080671A1 (en) 1993-04-22
JPH05201865A (ja) 1993-08-10
ATE116974T1 (de) 1995-01-15
CN1073168A (zh) 1993-06-16
ATE156821T1 (de) 1997-08-15
GR3024453T3 (en) 1997-11-28
DE69221634T2 (de) 1998-01-15
KR100214902B1 (ko) 1999-08-02
DE69221634D1 (de) 1997-09-18
DE69201184T2 (de) 1995-06-08
TW221429B (ko) 1994-03-01
EP0615971B1 (en) 1997-08-13
DK0541263T3 (da) 1995-04-18

Similar Documents

Publication Publication Date Title
RU2225404C2 (ru) ПРОИЗВОДНЫЕ ПИПЕРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ФАКТОРА Хa
RU2002107975A (ru) Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения
KR930007943A (ko) 벤조티아제핀 유도체
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
RU95120169A (ru) Производные пирролиденметила, способ их получения, промежуточные продукты, фармацевтическая композиция, способ лечения и/или профилактики
KR870007905A (ko) 나프토티아제핀온
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
KR920700207A (ko) 벤즈아제핀 및 벤조티아제핀 유도체
RU97103983A (ru) Лекарственные композиции и производные триазина
DK484787A (da) Bis-dioxopiperazin-derivater
NO890440L (no) Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
DE3874900D1 (de) Wirkstoff mit die nierenfunktion verbesserndem und diuretischem effekt und verwendung eines darin enthaltenen benzothiazepin-derivates.
AU563094B2 (en) 1,5-benzothiazepine derivatives
GB8320005D0 (en) Benzothiazoline derivatives
KR890016028A (ko) 5-{2-[n-(2-아미노-2-옥소에틸)메틸아미노]에틸}-3-히드록시-2-(4-메톡시페닐)-2,3-디히드로-1,5(5h)-벤조티아제핀-4-온 유도체, 그의 제법 및 치료에의 이용
SE8403042L (sv) Hypolipidemisk komposition
KR880003914A (ko) 5-메틸-10,11-디하이드로-5H-디벤조-[a,d] 사이클로헵텐-5,10-이민의 유도체
DE50013571D1 (de) Arzneimittel zur behandlung von neuropathien
SE9201609D0 (sv) Foerfarande foer framstaellning av bensotiazepiner genom cyklisering med fosfonsyror
KR870008865A (ko) 나프토티아조시논
ATE269862T1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften
GB2190290B (en) Use of benzothiazepine derivatives in pharmaceutical compositions for improving constitution of lipids in blood.
KR890002074A (ko) 나프토티아조시논
JPS649982A (en) 1,5-benzothiazepine derivative
EE03565B1 (et) 3-hüdroksü-5-[2-(dimetüülamino)etüül]-2,3-dihüdro-2-(4-metoksüfenüül)-1,5-bensotiasep iin-4(5H)-ooni, selle derivaatide ja farmakoloogiliste ühendite valmistamise meetod

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19921020

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970107

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19921020

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19981231

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19990330

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990520

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990521

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20020403

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20020403

Start annual number: 4

End annual number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20040210